

- 24 both IgG1 and IgM responses to the SARS-CoV-2 spike protein receptor binding domain (RBD).
- 25 IgM⁺ memory, but not switched memory, directly correlated with virus-specific antibody
- 26 responses, and remained stable over time. Our findings suggest that the frequency of memory
- 27 B cells is a critical indicator of disease resolution, and that IgM⁺ memory B cells play an
- 28 important role in SARS-CoV-2 immunity.

29 **Introduction**

30 There have now been over 24 million reported cases of SARS-CoV-2, including at least 830,000 31 deaths worldwide (1). As the work to develop effective vaccines and therapies to control the 32 pandemic progresses, it is important to develop reliable approaches for assessing durable 33 immunological memory. Identification of a correlate of immunity to SARS-CoV-2 has been 34 challenging, as clinical presentation and serological profiles vary between patients. Rare SARS-35 CoV-2-specific antibodies with potent neutralizing capacity have been isolated from recovered 36 COVID-19 patients (2). Additionally, acute COVID-19 patients have been observed to have 37 perturbations of immune profiles, and have been grouped into three or more immunotype 38 clusters (3). On the basis of these findings, we focused on correlates of clinical outcomes in 39 convalescent plasma donors that could be inferred through cell-based assays. Recent studies 40 have correlated B cell responses in some individuals with immunity and protection (4).

41 B cells participate in the antiviral immune response by first rapidly releasing germline or near-42 germline antibodies from plasmablasts, via an extrafollicular pathway. Upon T cell-mediated 43 CD40 ligation and appropriate cytokine stimulation, B cells undergo class switching and/or enter 44 germinal centers within secondary lymphoid organs to undergo affinity maturation. This 45 maturation process produces both long-lived plasma cells and memory B cells capable of 46 responding to secondary challenge with homotypic or heterotypic antigenic challenge.

47 While many studies of the B cell response to SARS-CoV-2 have focused on plasmablast 48 expansion, the benefit of this expansion has not been clear (3, 5, 6). Indeed, clinical outcome 49 correlations suggest that extrafollicular B cell activation and subsequent plasmablast generation 50 are detrimental to host survival and COVID-19 symptom resolution. Memory B cells are also 51 generated following SARS-CoV-2 infection (4). B memory cells are found as multiple subsets, 52 including canonical CD27⁺ class-switched memory B cells, but also activated CD24-negative

61 **Results**

62 *Longitudinal sampling of plasma donors with previous SARS-CoV-2 infection*

63 To assess clinically-informative phenotypic characteristics of the B cell response in 64 convalescent plasma donors, we evaluated peripheral blood PBMCs from this cohort and 65 healthy volunteers by flow cytometry. Forty convalescent donors were recruited through the 66 State University of New York Upstate Medical University Clinical Research Unit. They were 67 sampled at an average of 69 days post-symptom onset, were a mean age of 51.6 years, and 68 were composed of 35% males and 65% females. Donors were predominately white and non-69 Hispanic **(Supplemental Figure 1)**. Convalescent donors were recruited following a positive 70 SARS-CoV-2 PCR and at least 2 weeks following the last symptom, or for asymptomatic 71 subjects, after a repeat SARS-CoV-2 PCR test that was negative. Seventeen subjects were also 72 sampled at a 3-month follow-up visit. This latter subset included asymptomatic subjects, as well 73 as those sampled in early, mid, and late convalescence. Characteristics of the study population 74 are summarized in **Figure 1**.

75 *B cell profiles varied widely during SARS-CoV-2 convalescence both between and within* 76 *individuals*

77 As has been observed in other studies (2, 5), the B cell profiles of convalescent plasma donors 78 were diverse. Using a well-defined gating strategy described by Sanz et al. (7) **(Supplemental** 79 **Figure 2)**, we identified convalescent subjects with expanded B cell memory, a robust 80 plasmablast population, and a B cell phenotype resembling that of many healthy control 81 samples (Figure 2a). We did not observe a difference in total CD19⁺ B cell frequency between 82 convalescent and healthy subjects **(Figure 2b)**, but convalescent naïve, transitional, and 83 activated B cell frequencies followed the inverse trend of memory frequencies over time **(Figure** 84 **2c-f)**. Memory B cell frequencies ranged widely, in both convalescent subjects and healthy

85 controls **(Figure 2d)**. The plasmablast compartment was the only major B cell subset analyzed 86 that remained significantly skewed in the convalescent phase compared to healthy controls 87 **(Figure 2b-g)**. Moreover, elevated plasmablast frequencies were only observed in a subset of 88 subjects.

89 To further examine memory B cells in convalescent subjects, we visualized the flow cytometry 90 datasets using an unbiased t-distributed stochastic neighbor embedding (t-SNE) algorithm 91 **(Figure 3a)**. This approach allowed us to resolve populations within clusters that may not be 92 discrete using gating strategies alone, and assess marker expression within these clusters. The 93 majority of convalescent subjects had normal to elevated frequencies of both switched and 94 unswitched CD38-negative CD24⁺ memory B cells (Figure 3b-c). These data contrast with 95 observations of memory B cell loss in COVID-19 patients with acute disease (8). The peripheral 96 blood of convalescent subjects also contained a modest pool of activated CD38-negative CD24- 97 negative B cells, which were the primary clusters in which CD11c and T-bet were expressed 98 **(Figure 3a)**.

99 Given the demonstrated role of CD11c⁺ T-bet⁺ B cells in responses to viral antigens (9, 10), and 100 their presence during acute SARS-CoV-2 infection (4), we screened convalescent donor 101 samples for the presence of CD11c⁺ T-bet⁺ B cells. The frequency of both CD11c⁺ and T-bet⁺ B 102 cells were only slightly elevated in convalescent subjects compared to healthy controls, likely 103 reflecting a return to B cell homeostasis **(Figure 3d-e)**. Likewise, significantly elevated 104 frequencies of double-negative (DN) IgD-negative CD27-negative B cells were not observed in 105 convalescent subjects **(Figure 3f)** in our cohort. These finding suggests that activated and DN 106 populations may be preferentially involved in the early phase and/or critical clinical presentation 107 of SARS-CoV-2 infection, as observed by Woodruff et al. (5) during acute severe COVID-19. 108 These analyses reveal substantial heterogeneity not just in the B cell immunophenotype 109 between subjects, but also within the B cell memory compartment itself.

110 Shorter symptom duration was correlated with increased switched and IgM⁺ memory B

111 *cell frequencies in convalescent subjects*

112 While we observed diverse B cell subsets in convalescent subjects, it was still unclear which, if 113 any, of these subsets were correlated with clinical outcomes following symptomatic COVID-19 114 infection. An association between frequencies of memory B cells and enhanced recovery 115 following COVID-19 pneumonia was reported (8). We therefore analyzed our B cell 116 immunophenotyping dataset for its correlation with self-reported symptoms in our convalescent 117 cohort. Our analysis revealed a significant negative correlation between the duration of COVID-118 19 symptoms and the frequency of memory B cells within the B cell compartment, as well as for the IgM⁺ 119 memory B cell subset **(Figure 4a-b)**. A similar trend was observed for switched 120 memory B cell frequency **(Figure 4c)**.

121 To determine whether these observations were due solely to the time of sampling, we analyzed 122 the frequency of B cell subsets in convalescent subjects and the number of days between last 123 symptom and sample collection, as well as the number of days between symptom onset and 124 sampling. IgM⁺ and switched memory B cell frequencies were stable or enhanced over time. We 125 failed to observe a correlation between $IgM⁺$ or switched memory B cell frequency with the time 126 since the last reported symptom **(Figure 4d-e)**, or the time since symptom onset **(Figure 4g-h)**. 127 As was expected, longer symptom duration correlated with increased frequency of naïve and 128 transitional B cells, due to contraction of the plasmablast response **(Figure 4g-k)**. Neither age 129 nor gender were observed to have a statistically significant influence on any of the clinical or 130 immunophenotypic parameters examined in this dataset (data not shown).

131 Several studies have reported robust expansion of peripheral blood plasmablasts during SARS-132 CoV-2 infection in some patients (5, 6). In agreement with these data, our cohort of 133 convalescent subjects contained individuals with dramatically elevated frequencies of CD38^{hi}

134 CD24-negative CD19⁺ plasmablasts (Figure 1g). Despite this trend, this subset was not 135 significantly correlated with the duration of COVID-19 symptoms at the time point at which we 136 sampled **(Figure 4l)**. Plasmablast frequency among convalescent B cells did appear to wane 137 over the time since last symptom, and symptom onset, confirming the contraction of the acute 138 response **(Figure 4f, i)**. Collectively, these data suggest that the presence of B cell memory is a 139 durable clinical correlate of shorter duration of COVID-19 disease.

140 *Memory B cell frequency was correlated with anti-RBD antibody production*

141 We next addressed whether the frequency of B cell memory in convalescent subjects correlated 142 with the generation of anti-spike receptor-binding domain (RBD) antibodies. The spike RBD is 143 thought to be required for SARS-CoV-2 binding and entry via the ACE2 receptor, and both 144 inhibitory and neutralizing anti-RBD antibodies have been identified in infected and recovered 145 subjects (4, 11). In seropositive convalescent subjects, IgG1 and IgM anti-spike RBD were 146 significantly correlated with CD24⁺ CD38-negative memory B cell frequency **(Figure 5a-b, f)**. 147 This was not observed for IgG2, IgG3, or IgG4 **(Figure 5c-e**; for full cohort, see **Supplemental** 148 **Figure 5)**.

149 The positive relationship between IgG1 and memory held for IgM⁺ memory B cells **(Figure 5g)**,

150 but not for switched memory **(Figure 5j)**. For almost all anti-RBD IgG1-producing subjects, there

151 was a nearly dose-dependent correlation between and anti-RBD IgG1 and IgM⁺ memory B cell

152 frequency. IgM anti-RBD was significantly correlated with both switched and unswitched

153 memory, though not as markedly **(Figure 5i & l)**. Memory B cell frequency and total

154 immunoglobulin levels were largely unrelated, except for a weak positive correlation between

155 memory and total IgG2 **(Supplemental Figure 5g-l)**.

156

157 *Memory B cell frequencies were maintained or increased as plasmablasts returned to* 158 *baseline.*

159 We next addressed whether the memory B cells were a stable population, or waned, as did the 160 plasmablast response. We re-sampled a subset of the convalescent cohort at least 3 months 161 after the initial visit **(Figure 1, Supplemental Figure 1)**. Results from this longitudinal analysis 162 showed a contraction of the plasmablast response **(Figure 6a)**. We also observed that memory 163 B cell frequencies and subset distribution were maintained or increased in most subjects 164 **(Figure 6b-d)**. Naïve B cell frequency remained nearly constant **(Figure 6e)**, and transitional 165 subset frequencies fluctuated over time, without exhibiting a trend **(Figure 6f)**. Although data 166 from individual subjects demonstrated temporal variability with regards to the frequency of 167 activation-associated B cell subsets, the frequency of T-bet⁺, CD11c⁺, DN, and activated B cells 168 did not change significantly over time for the cohort as a whole **(Figure 6g-j)**. These trends were 169 not obviously impacted by the stage of convalescence when the first sample was obtained. 170 None of the B cell subsets analyzed exhibited statistically significant changes over the 3-month

171 period wherein we assessed our convalescent cohort, although the plasmablast compartment 172 contraction suggests a return to B cell homeostasis. These findings support a role for switched 173 and unswitched memory B cells in the maintenance of stable, durable SARS-CoV-2 immunity.

174 **Discussion**

175 In this study we identified both unswitched and switched B cell memory as a correlate of shorter 176 COVID-19 symptom duration. Moreover, IgM⁺ memory correlated strongly with the anti-RBD 177 IgG1 antibody response. These data suggest that a protective memory response occurs in at 178 least some COVID-19 patients, preceded or accompanied by the generation of IgM⁺ memory B 179 cells. We envision three possible explanations for these findings. First, it is possible that 180 memory B cells identified in some individuals were generated in response to a previous 181 coronavirus infection. Coronaviruses as a group likely generate cross-reactive B and T cells 182 responses (12). The observation that the anti-RBD $\log 1$ response was correlated with $\log M^+$ 183 memory cell frequency is paradoxical, however, given that IgM⁺ memory cells don't produce 184 switched immunoglobulin. We propose that IgM⁺ memory cells are generated in abundance 185 during coronavirus infections, and that some of these enter germinal centers and undergo class 186 switching following a related coronavirus infection, thereby contributing to enhanced IgG1 187 production. The capacity of IgM⁺ memory cells to preferentially enter germinal centers upon 188 activation has been well-documented in mouse and human studies (13, 14, 15). This 189 characteristic versatility of IgM⁺ memory cells could be advantageous for immunity to 190 pathogens, such as the coronaviruses, where infections with closely related strains often occur.

191 The lack of correlation between the frequency of resting memory B cells and CD11c⁺ and/or T-192 bet⁺ B cells in convalescent subjects was unexpected, given the pivotal role these molecules 193 play in type-1 B cell immunity. We hypothesize that these factors may play a key role during the 194 acute phase and during chronic viral infections, but are not essential during the convalescent 195 phase of SARS-CoV-2 infection. Additional prospective studies and kinetic analyses of 196 previously-exposed and naïve individuals will help to resolve this question.

197 A second explanation for the enhancement of COVID-19 recovery coincident with memory B 198 cell expansion, is that naïve subjects whose B cells received more efficient T cell help during 199 primary infection generated a larger pool of memory B cells. This explanation is consistent with 200 the close relationship between memory and pathogen-specific antibody production we 201 observed. This explanation would suggest that T cells contributed to a better germinal center 202 response in some individuals. In contrast, subjects whose B cells received insufficient or 203 inappropriate T cell help would generate poor germinal center reactions, fewer antigen-specific 204 antibodies, and have a longer symptomatic disease period.

205 T cell help occurs largely within germinal centers, suggesting that the local immune environment 206 may be critical for an adequate response to SARS-CoV-2. Indeed, severe disruption of 207 lymphatic tissue organization and germinal center formation have been observed in severe 208 COVID-19 cases (16). Moreover, studies from our laboratory have shown that follicle 209 architecture disruption, acute plasmablast expansion, and type-1 cytokine skewing occurs 210 during murine intracellular bacterial infection $(17–19)$. We observed IgM⁺ memory to be 211 protective during *E. muris* infection, despite severe immunopathology associated with primary 212 infection. In this way, it is possible that the germinal center disruption caused by SARS-CoV-2 213 infection also contributes to the generation of protective IgM⁺ B cell memory. The data herein 214 suggests that IgM⁺ memory B cells may complement long-lived plasma cells generated via 215 germinal centers and provide protection against subsequent SARS-CoV infection.

216 Finally, the benefit of memory B cell expansion may only be an indication that acute 217 inflammation and excessive cytokine production did not occur in some individuals. Under 218 inflammatory conditions, such as those occurring in systemic lupus erythematous (SLE), B cell 219 subsets have been shown to be skewed toward an activated, extrafollicular effector fate (20). It 220 has been suggested that B cell responses to severe acute COVID-19 disease have similar 221 characteristics to those observed in SLE (5). The variability in the penetrance of this phenotype

222 may be explained by the influence of gender and pre-existing autoimmunity. Future work using 223 animal models of COVID-19 may help to resolve these questions.

224 Our studies support other work that has reported that germinal center-derived memory B cells 225 are likely generated following SARS-CoV-2 infection, and that these memory B cells are a 226 durable correlate of an effective primary response (4, 8). These studies challenge early claims 227 of waning immunity shortly after SARS-CoV-2 infection. Our data also show that some 228 individuals can be identified as having better natural immunity. We also propose that both IgM⁺ 229 and switched memory B cells may provide a good indication of vaccine efficacy, and that 230 individuals with large numbers of $IqM⁺$ memory B cells may be better protected from future re-231 infection with homotypic or heterotypic infection. Our findings suggest that IgM⁺ memory B cells 232 are central to the COVID-19 adaptive immune response, and highlight the need for prospective 233 SARS-CoV-2 studies to determine whether large memory B cell populations are a pre-existing 234 correlate of protection, or a durable measure of the antiviral immune response.

235 **Methods:**

236 Study Design

237 Study participants were recruited at the SUNY Upstate Medical University Clinical Research 238 Unit starting from March 2020 and is ongoing. Participants meeting eligibility criteria were adults 239 aged 18 or older who have tested positive for SARS-CoV-2 and are at least 14 days past their 240 first symptom. Exclusion criteria included the inability to give informed consent and/or an 241 inability to donate plasma or blood transfusion in the past. Study participants were interviewed 242 by study staff, and presented to the SUNY Upstate Clinical Research Unit for peripheral blood 243 collection. Information regarding symptoms, including dates of first and last symptom, was self-244 reported. Donors were questioned about acute symptoms such as fever, shortness of breath, 245 sore throat, cough that impacted activity, and fatigue that impacted activity. These indications 246 were used to calculate dates of symptoms retrospectively. Lingering symptoms such as loss of 247 taste and smell, mild cough or tickle in the throat, or lingering fatigue that did not impact their 248 daily activity were not considered part of the acute illness and therefore not included in the 249 length of illness. For donors reporting no symptoms, the date of positive RT-PCR test was used 250 for the start and stop date of symptoms. These subjects were not included in correlative 251 analysis of symptom duration. Healthy control subjects were adults aged 18 or older who denied 252 infection with or known exposure to SARS-CoV-2. Healthy controls were screened by anti-RBD 253 plasma ELISA to confirm negative exposure status. Sample size was determined based on 254 subject availability. All samples were de-identified following collection, and researchers 255 conducting assays were blinded to clinical data until final comparative analysis.

256 Blood sample processing and storage

257 PBMCs were obtained following gradient centrifugal separation of peripheral blood using Cell 258 Preparation Tubes (CPT) (BD) for 30 minutes at 1700 x g. Plasma was separated, aliquoted,

259 and stored at -20°C for antibody assays. The mononuclear layer was washed in PBS prior to 260 counting on a Coulter particle counter (Becton-Dickinson). PBMCs were either directly stained 261 for flow cytometry (initial visit samples), or frozen slowly to -80°C in FBS and DMSO for short-262 term storage (3-month visit samples). Flow cytometry panel was validated using a sample of 263 fresh vs. frozen PBMCs to ensure comparability in target detection. Plasma samples were heat-264 inactivated (56°C for 30 minutes) prior to use in assays.

265 Flow Cytometry

266 The following antibodies used for flow cytometry were obtained from BioLegend: CD21 (Bu32), 267 T-bet (4B10), CD38 (HIT2), CD11c (Bu15), CD3 (HIT3A), CD14 (HCD14), IgD (IA6-2), CD24 268 (MC5), IgM (MHM-88), CD27 (O323), and CD19 (HIB19). For flow cytometric analysis, single-269 cell suspensions were incubated with 1 microg/ml anti-CD16/CD32 in 2% normal goat 270 serum/HBSS/0.1% sodium azide (Fc blocking solution). The cells were then stained with aqua 271 Live/Dead stain (Invitrogen) and washed prior to incubation with mAbs. Cells were fixed, 272 permeabilized, and stained for intracellular targets using an intracellular staining kit (BD). 273 Unstained controls were used to set the flow cytometer photomultiplier tube voltages, and 274 single-color positive controls were used to adjust instrument compensation settings. Data from 275 stained samples were acquired using a BD Fortessa flow cytometer equipped with DIVA 276 software (BD Biosciences) and were analyzed using FlowJo software (Tree Star). t-SNE 277 visualization was generated using FlowJo automatic (opt-SNE) learning configuration, with 1000 278 iterations, a perplexity of 30, learning rate of 3179, exact KNN algorithm, and Barnes-Hut 279 gradient algorithm.

280 ELISA protocol

281 Plasma samples were first heat-inactivated at 56°C for 30 mins before use in assays. 282 Recombinant Twin-Strep-tagged RBD protein was purified from 293T cells transfected with

283 pαH-RBD SD1-3CH25, generously provided by Jason S. McLellan (University of Texas), as 284 previously described (21). RBD protein was coated on Strep-Tactin® microplates plates (IBA, 285 Germany) in binding buffer (100mM Tris pH 8, 150mM NaCl, 1mM EDTA) overnight at 4°C. 286 Plates were washed three times with PBS-T (1x PBS/0.05% Tween-20) and subsequently 287 blocked with 3% BSA (Sigma) in PBS-T for 1 hour at RT. Diluted plasma was loaded onto plates 288 and incubated for 2 hours at RT. After incubation, plates were washed three times with PBS-T 289 and HRP-conjugated secondary anti-human antibodies were used for detection. Total IgG was 290 detected using goat-anti-human-IgG-HRP (Rockland, #209-1304). IgM was detected using goat-291 anti-human-IgM-HRP (Sigma, #A6907), and IgG subclass antibodies were detected with mouse 292 horseradish peroxidase (HRP)-conjugated anti-human IgG1 (9054-05), IgG2 (9060-05), IgG3 293 (9210-05), and IgG4 (9200-05) from SouthernBiotech. Wells were washed three times with 294 PBS-T before the addition of HRP substrate SIGMAFAST OPD (Sigma, #P9187). Reaction was 295 quenched with 1M hydrochloric acid (Fisher Scientific, #S25856) and read at 490 nM on a 296 BioTek Synergy LX multi-mode plate reader. Area under the curve (AUC) analysis was 297 performed using peak identification set to a 10% minimum change from baseline. Plasma 298 ELISAs for total human immunoglobulin isotype quantitation were performed using the Human 299 Immunoglobulin Isotyping LEGENDplex 6-plex kit (BioLegend) according to the manufacturer's 300 instructions. Data were collected using a BD LSR II flow cytometer and analyzed using 301 LEGENDplex Data Analysis Software.

302 Statistical Analysis

303 Statistical analyses were performed using GraphPad Prism software (v8.4.3). Analysis of 304 correlation between flow cytometry, total serum immunoglobulin ELISA data, and continuous 305 clinical data was performed using Pearson correlation coefficients for data sets equal to or 306 larger than 35 values, or nonparametric Spearman's Rank correlation for data sets with fewer 307 than 35 values. *p*-values are two-tailed and 95% confidence intervals shown where noted in

308 figure legends. Statistical analysis of cell subset frequency between healthy and the total 309 convalescent donor cohort from flow cytometry assays was performed using unpaired 310 nonparametric Mann-Whitney test with two-tailed p-values and 95% confidence intervals. 311 Multiple comparison analysis between each convalescent subject subgroup was done with 312 Kruskal-Wallis test with Dunn's correction. Adjusted *p* value was used to determine family-wise 313 significance at alpha = 0.05. Statistical analysis of anti-RBD plasma ELISA data was performed 314 using area under the curve analysis with peak identification set to a 10% minimum change from 315 baseline. NS indicates a *p* value > 0.05, **p*, < 0.05, ***p*, < 0.01, ****p*, < 0.001, and *****p*, 316 <0.0001. The statistical tests performed are indicated in the figure legends. For column graphs, 317 the column in each plot indicates the arithmetic mean of the dataset, and upper and lower

- 318 bounds indicate SD of the dataset.
- 319 Study approval

320 All participants provided written informed consent prior to participation in the study, which was 321 performed according to a protocol approved by the Institutional Review Board (IRB) of the 322 SUNY Upstate Medical University under IRB number 1587400. All clinical investigation was 323 conducted according to Declaration of Helsinki principles.

324 Author contributions

325 K.L.N., H.E.T., J.R.W., and G.M.W. conceived, designed, and analyzed the experiments. T.P.E.

326 designed clinical protocols. K.L.N. and J.B.C. performed flow cytometry. D.C.C., Y.I.K. and

327 H.E.T. performed anti-RBD ELISAs, and V.Z.R. carried out total plasma Ig ELISAs. T.P.E.

328 recruited participants and executed clinical protocols. K.L.N. and J.B.C. processed clinical

329 samples. K.L.N. authored the manuscript, with editing by J.R.W., H.E.T., T.P.E., and G.M.W. All

330 authors reviewed and approved the manuscript.

331 Acknowledgments

- 332 We thank all study participants who made this work possible, the SUNY Upstate Medical
- 333 University Clinical Research Unit, Michelle Klick for research coordination, the SUNY Upstate
- 334 Institute for Global Health and Translational Science for research administration, Dongliang
- 335 Wang for assistance with statistical analysis, Mark Abbott and Kristen Baxter for critical
- 336 laboratory support, Lisa Phelps and Steven Taffet for support with the SUNY Upstate Medical
- 337 University flow cytometry core, and Russell Levack for helpful discussion. This work was
- 338 supported by U.S. Department of Health and Human Services Grant R01AI114545 (G.M.W.),
- 339 SUNY Office of Research and Economic Development seed grant RFP #20-03-COVID 202077
- 340 (J.R.W. and G.M.W.), and internal funding from SUNY Upstate Medical University.
- 341 Disclosures
- 342 The authors have declared that no conflict of interest exists.
- 343 Data Availability
- 344 All data generated or analyzed during this study are included in this article and supplementary
- 345 data, or available from the corresponding author upon reasonable request.

346 **References**

- 347 1. Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. *COVID-19*
- 348 *Dashboard* 2020;https://coronavirus.jhu.edu/map.html. cited
- 349 2. Robbiani DF et al. Convergent antibody responses to SARS-CoV-2 in convalescent
- 350 individuals [Internet]. *Nature* [published online ahead of print: June 18, 2020];
- 351 doi:10.1038/s41586-020-2456-9
- 352 3. Mathew D et al. Deep immune profiling of COVID-19 patients reveals patient heterogeneity
- 353 and distinct immunotypes with implications for therapeutic interventions. *BioRxiv Prepr. Serv.*
- 354 *Biol.* [published online ahead of print: May 23, 2020]; doi:10.1101/2020.05.20.106401
- 355 4. Rodda LB et al. *Functional SARS-CoV-2-specific immune memory persists after mild COVID-*
- 356 *19 [Internet]*. Infectious Diseases (except HIV/AIDS); 2020:
- 357 5. Woodruff M et al. *Dominant extrafollicular B cell responses in severe COVID-19 disease*
- 358 *correlate with robust viral-specific antibody production but poor clinical outcomes [Internet]*.
- 359 Allergy and Immunology; 2020:
- 360 6. Kuri-Cervantes L et al. *Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection* 361 *[Internet]*. Immunology; 2020:
- 362 7. Sanz I et al. Challenges and Opportunities for Consistent Classification of Human B Cell and 363 Plasma Cell Populations. *Front. Immunol.* 2019;10:2458.
- 364 8. De Biasi S et al. Expansion of plasmablasts and loss of memory B cells in peripheral blood 365 from COVID‐19 patients with pneumonia. *Eur. J. Immunol.* 2020;eji.202048838.

- 366 9. Knox JJ et al. T-bet+ B cells are induced by human viral infections and dominate the HIV
- 367 gp140 response. *JCI Insight* 2017;2(8). doi:10.1172/jci.insight.92943
- 368 10. Rubtsova K, Rubtsov AV, van Dyk LF, Kappler JW, Marrack P. T-box transcription factor T-
- 369 bet, a key player in a unique type of B-cell activation essential for effective viral clearance. *Proc*
- 370 *Natl Acad Sci U A* 2013;110(34):E3216-24.
- 371 11. Premkumar L et al. The receptor binding domain of the viral spike protein is an
- 372 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci. Immunol.*
- 373 2020;5(48). doi:10.1126/sciimmunol.abc8413
- 374 12. Mateus J et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed
- 375 humans. *Science* 2020;eabd3871.
- 376 13. Kenderes KJ et al. T-Bet + IgM Memory Cells Generate Multi-lineage Effector B Cells. *Cell* 377 *Rep.* 2018;24(4):824-837.e3.
- 378 14. Weill J-C, Reynaud C-A. IgM memory B cells: specific effectors of innate-like and adaptive
- 379 responses. *Curr. Opin. Immunol.* 2020;63:1–6.
- 380 15. Seifert M et al. Functional capacities of human IgM memory B cells in early inflammatory
- 381 responses and secondary germinal center reactions. *Proc. Natl. Acad. Sci. U. S. A.*

382 2015;112(6):E546-555.

- 383 16. Kaneko N et al. The Loss of Bcl-6 Expressing T Follicular Helper Cells and the Absence of
- 384 Germinal Centers in COVID-19 [Internet]. *SSRN Electron. J.* [published online ahead of print:
- 385 2020]; doi:10.2139/ssrn.3652322

- 386 17. Popescu M, Cabrera-Martinez B, Winslow GM. TNF-α Contributes to Lymphoid Tissue
- 387 Disorganization and Germinal Center B Cell Suppression during Intracellular Bacterial Infection.
- 388 *J. Immunol.* 2019;ji1900484.
- 389 18. Racine R, Chatterjee M, Winslow GM. CD11c expression identifies a population of
- 390 extrafollicular antigen-specific splenic plasmablasts responsible for CD4 T-independent antibody
- 391 responses during intracellular bacterial infection. *J Immunol* 2008;181(2):1375–85.
- 392 19. Levack RC, Newell KL, Popescu M, Cabrera-Martinez B, Winslow GM. CD11c+ T-bet+ B
- 393 Cells Require IL-21 and IFN-γ from Type 1 T Follicular Helper Cells and Intrinsic Bcl-6
- 394 Expression but Develop Normally in the Absence of T-bet. *J. Immunol. Baltim. Md 1950*
- 395 2020;205(4):1050–1058.
- 396 20. Jenks SA, Cashman KS, Woodruff MC, Lee FE, Sanz I. Extrafollicular responses in humans 397 and SLE. *Immunol Rev* 2019;288(1):136–148.
- 398 21. Wrapp D et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
- 399 *Science* 2020;367(6483):1260–1263.

Figure 1. Study design and clinical data. (a) Graphical representation of convalescent subject groupings and gender. All grouping and subset designations were done retrospectively. **(b)** Symptom and sampling timeline for symptomatic subjects, ordered by length of convalescence.

 $II. 5.10$

Healthy

III. 53.8

I. Memory

- $II. T1 + T2$
- III. Naïve + T3

CD24

- IV. aNaïve + aMBC
- V. Pre-PB + PB

5

10

15

20

B cells **B cells**

ns

(c)

20 40 60 80 100 Naive + T3 **nsNaïve + T3**

ns

 ns

% CD24int CD38int

CD24^{Int} CD38Int

Figure 2. The B cell profiles of individual convalescent plasma donors were diverse. (a) Representative flow plots of live, singlet, CD19+ lymphocytes demonstrating 5 primary B cell subsets in one healthy and 4 convalescent subjects. **(b-d)** Histograms of healthy vs. convalescent donor frequencies of **(b)** total CD19+ B cells, and **(c)** naïve, **(d)** memory, **(e)** transitional 1 and 2, **(f)** activated naïve/memory, and **(g)** plasmablast subsets among viable CD19+ lymphocytes. Bars represent mean +/- SD. Multiple comparison analysis between each donor subgroup was done with Kruskal-Wallis test with Dunn's correction. Adjusted p value was used to determine family-wise significance at alpha = 0.05. Healthy control and total convalescent groups also compared by Mann-Whitney test with two-tailed p value, $alpha = 0.05$.

Figure 3. Convalescent plasma donor B cell compartments were heterogeneous and enriched for memory B cells. (a) tSNE representation sub-gated to highlight key clusters of viable CD19+ lymphocytes from a representative convalescent donor with an enriched memory B cell subset. Heatmap overlay shows median expression for each target. **(b-f)** Healthy and convalescent donor cell frequencies for **(b)** IgM⁺ memory, (c) switched Memory, (d) CD11c⁺, (e) T-bet⁺, and (f) DN subsets among viable CD19⁺ lymphocytes. Bars represent mean +/-SD. Multiple comparison analysis between each donor subgroup was done with Kruskal-Wallis test with Dunn's correction. Adjusted p value was used to determine family-wise significance at alpha = 0.05.

Figure 4. The frequency of memory B cells in the peripheral blood was correlated with shorter symptom duration following infection with SARS-CoV-2, and stable over time. (a-c) Scatterplot correlation of symptom duration in days, vs. the frequency among viable CD19+ B cells of **(a)** total memory, **(b)** IgM+ memory, and **(c)** switched memory. **(d-f)** Scatterplot correlation of days since last symptom vs. **(d)** IgM+ memory, **(e)** switched memory, and **(f)** plasmablast frequency among viable CD19+ lymphocytes. **(g-i)** Scatterplot correlation of days since symptom onset vs. **(g)** IgM+ memory, **(h)** switched memory, and **(i)** plasmablast frequency among viable CD19+ B cells. **(j-l)** Scatterplot correlation of symptom duration in days, vs. **(j)** naïve and transitional type 3, **(k)** transitional type 1 and 2, and **(l)** plasmablast frequency among viable CD19+ B cells. Pearson's correlation r value and 95% confidence intervals shown with two-tailed p values, alpha = 0.05 .

Figure 5. Anti-spike receptor binding domain antibody levels correlated with memory B cell frequency in convalescent plasma donors. (a-f) Scatterplot correlation of area under the curve for anti-RBD plasma absorbance vs. memory B cell frequency from convalescent subjects seropositive for each isotype (IgG1 & IgG3 *n* = 15, IgM *n* =16). Subjects whose data points are circled in **(a)** were isolated for statistical analysis of IgG1 in **(b, g, and j**; *n* = 12**)**. **(g-i)** Scatterplot correlation of area under the curve for anti-RBD plasma absorbance vs. IgM+ memory B cell frequency among viable CD19+ lymphocytes. **(j-l)** Scatterplot correlation of area under the curve for anti-RBD plasma absorbance vs. switched memory B cell frequency among viable CD19* lymphocytes. Spearman's correlation r_s value and 95% confidence intervals shown with two-tailed p value, alpha = 0.05 for all analyses.

Figure 6. Convalescent SARS-CoV-2 subjects displayed a contraction of plasmablasts over time, but maintained memory B cells. (a-j) Frequency of **(a)** plasmablasts, **(b)** total memory, **(c)** switched memory, **(d)** IgM+ memory, **(e)** naïve + transitional 3, **(f)** transitional 1 + 2, **(g)** T-bet+, **(h)** CD11c+, **(i)** DN, and **(j)** activated cells among CD19+ viable lymphocytes from 15 convalescent plasma donors at initial draw and 3-month follow-up visit. Each pair of connected points (and color) represents an individual subject. Symbol shapes indicate convalescent subset. Bars represent mean. Two donors (one asymp., one late conv.) were omitted due to B cell abnormalities likely unrelated to SARS-CoV-2.

Supplemental figure 1. Demographic data. (a-c) Distribution of **(a)** gender, **(b)** age, and **(c)** ethnicity among the convalescent plasma donor cohort (*n* = 40). **(d-e)** Distribution of **(d)** gender and **(e)** age among healthy donors (*n* = 24). **(f-g)** Distribution of **(f)** gender and **(g)** age among the subset convalescent plasma donor cohort (*n* = 15) analyzed in figure 6 three months after initial visit. **(h)** Cumulative table of demographic data.

Supplemental figure 2. Flow cytometry gating strategies for B cell subset analysis. (a) Representative plots demonstrating gating strategy for flow cytometric identification of B cell subsets. **(b)** Flow chart showing the dichotomy and subset discrimination used to assess B cell subsets from peripheral blood PBMCs.

Supplemental Figure 3: Correlation matrix. Spearman's r correlation coefficients between variables on opposing axes for convalescent plasma donor cohort (*n* = 40, except for total Ig's: *n* = 39, and T-bet: *n* = 35). Data collected and analyzed as described in **figure S2** (flow cytometry gating) and **figure 5 (**plasma antibody assays).

Supplemental Figure 4. Anti-spike receptor binding domain-specific and total antibody levels do not correlate with symptom duration in full cohort of convalescent plasma donors. (a-e) Scatterplot correlation of area under the curve for plasma anti-RBD absorbance vs. symptom duration for individual Ig isotypes and subclasses. **(f-k)** Scatterplot correlation of total plasma antibody concentration vs. symptom duration for individual Ig isotypes and subclasses. Pearson's correlation r value and 95% confidence intervals shown with two-tailed p value, alpha = 0.05.

Supplemental Figure 5. Memory B cell frequency correlation with anti-RBD antibody and total immunoglobulin in full cohort of convalescent plasma donors. (a-e) Scatterplot correlation of area under the curve for anti-RBD plasma antibody absorbance vs. memory B cell frequency for individual Ig isotypes and subclasses. **(g-l)** Scatterplot correlation of total plasma antibody concentration vs. memory B cell frequency from all convalescent subjects. Pearson's correlation r value and 95% confidence intervals shown with two-tailed p value, $alpha = 0.05$.